ImmunityBio faces multiple securities fraud class actions following an FDA warning letter dated March 13, 2026, that accused the company of misbranding its cancer drug Anktiva through false promotional claims. The letter, made public on March 24, 2026, alleged that television and podcast advertisements created a misleading impression that Anktiva could cure and prevent all cancer types, violating the Federal Food, Drug, and Cosmetic Act. The revelation triggered a sharp market reaction: ImmunityBio stock (NASDAQ: IBRX) fell 21% on March 24, 2026, leading investors who purchased shares during the class period from January 19, 2026, through March 24-25, 2026, to file lawsuits alleging that company leadership made materially false and misleading statements about the drug’s capabilities and the company’s business prospects.
Multiple law firms have filed class actions on behalf of affected investors, including Rosen Law Firm, Robbins Geller Rudman & Dowd LLP, Pomerantz LLP, and Portnoy Law Firm. Investors who suffered losses have until May 26, 2026, to seek appointment as lead plaintiff in these actions. This article explains what happened, who is eligible to participate, what the allegations contain, and what steps investors can take if they held ImmunityBio shares during the class period.
Table of Contents
- What Triggered the ImmunityBio Class Actions?
- The Legal Allegations Against ImmunityBio and Its Leadership
- Who Are the Defendants and What Do They Stand Accused Of?
- Who Is Eligible to Participate in the Class Action and What Are the Key Deadlines?
- The Law Firms Pursuing the Class Actions and How Multiple Cases Affect Investors
- The Broader Context: Cancer Drug Claims and Regulatory Scrutiny
- What Happens Next and Timeline for Potential Recovery
What Triggered the ImmunityBio Class Actions?
The catalyst for these lawsuits was the FDA warning letter targeting Anktiva’s promotional campaign. The letter, issued March 13, 2026, stated that promotional materials—specifically a television advertisement and podcast—overstated the drug’s proven benefits and created a false impression that Anktiva could cure and prevent multiple cancer types. The FDA does not approve drugs as cures for broad disease categories without comprehensive clinical evidence demonstrating efficacy across diverse populations and cancer subtypes. Promotional claims that go beyond what the FDA has approved in the drug’s label violate federal law and constitute drug misbranding. The public disclosure of the FDA warning on March 24, 2026, caused immediate investor reaction. The stock plunged 21% on that single day, erasing substantial shareholder value.
This sharp decline suggests that market participants had not previously understood the extent of the regulatory issues surrounding Anktiva’s marketing. In comparable cases, such regulatory surprises often indicate that the company’s prior public statements about the drug’s prospects or regulatory compliance may not have been accurate or sufficiently cautious. The timing matters legally. The class action period begins January 19, 2026, roughly two months before the FDA letter became public. This period captures investors who entered positions based on the company’s statements during a window when material information about regulatory problems was not yet disclosed. Investors who bought shares after March 24, 2026, when the FDA warning was public, would not be eligible for the class action since they had access to the warning letter when making their investment decisions.
The Legal Allegations Against ImmunityBio and Its Leadership
The lawsuits allege that ImmunityBio and its defendants violated the Securities Exchange Act of 1934 by making false and/or misleading statements about the company’s business, operations, and prospects. According to the complaints, company leadership, including Patrick Soon-Shiong (the company’s founder and majority shareholder), materially overstated Anktiva’s capabilities and commercial potential. The false statements allegedly relate not only to Anktiva but to the broader business claims made to investors about the company’s pipeline and regulatory standing. Securities fraud cases in this context typically rest on two key elements: (1) that the company made specific statements that were false or misleading when made, and (2) that investors relied on those statements when deciding to buy or hold shares.
The discovery phase of the lawsuit will likely examine internal communications, clinical trial data, regulatory correspondence, and marketing materials to determine what the company actually knew about Anktiva’s efficacy and what was communicated to the public and investors. However, if material internal communications show that company insiders were aware of regulatory risks but did not disclose them publicly, that evidence can strengthen claims of deliberate misrepresentation. One important limitation to note: Securities class actions do not require proof that defendants acted with malicious intent, only that they made statements that were materially false or misleading. A company might have made optimistic statements in good faith while being wrong about the science or regulatory landscape—courts have held that such mistakes can still constitute securities fraud if the statements were false when made and investors relied on them.
Who Are the Defendants and What Do They Stand Accused Of?
The primary defendants named in the class actions are ImmunityBio Inc. and Patrick Soon-Shiong. Soon-Shiong is a billionaire healthcare entrepreneur who controls a large stake in ImmunityBio and has served in leadership roles at the company. The lawsuits allege that Soon-Shiong and the company made materially false statements about Anktiva’s therapeutic potential, clinical readiness, and regulatory pathway. The inclusion of both the company and individual executives is standard in securities fraud cases, as courts permit shareholders to pursue claims against both the entity and the individuals responsible for public communications. The specific allegations involve overstatement of Anktiva’s capabilities.
Rather than describing the drug as a development-stage immunotherapy candidate being studied for certain cancer indications, the promotional materials allegedly portrayed it as a broad-spectrum cancer solution. This distinction is material to investors because development-stage drugs carry significant clinical and regulatory risk. A drug that is still in clinical trials and has not yet received FDA approval for any indication is fundamentally different in value and risk profile from one that is approved for actual use in patients. When companies or their leaders blur this line in marketing materials, they create a misleading picture of the company’s commercial prospects and the asset’s value. Other company officers and directors may be named in the lawsuits as well, depending on their involvement in the statements or oversight of the marketing campaign. The discovery process will reveal which individuals received or reviewed the promotional materials before publication and whether internal warnings about regulatory compliance were raised and ignored.
Who Is Eligible to Participate in the Class Action and What Are the Key Deadlines?
Investors are eligible for the ImmunityBio class actions if they purchased or acquired ImmunityBio publicly traded securities (common stock, options, or other equity instruments) during the class period from January 19, 2026, through March 24-25, 2026, inclusive. This period captures the window during which the FDA warning letter existed but was not yet public. Investors who bought shares before January 19, 2026, or after March 24-25, 2026, are not part of the eligible class. Similarly, investors who sold their shares before the class period began and repurchased them during the period may have complex eligibility situations that require consultation with a class action attorney. The most critical deadline is May 26, 2026, which is the lead plaintiff deadline. Investors who wish to play an active role in the lawsuit and potentially seek appointment as lead plaintiff must submit declarations to the court by this date.
The lead plaintiff is responsible for overseeing the case, working with counsel, and approving any settlement. Investors who do not seek lead plaintiff status but remain part of the class will be bound by the outcome and any settlement reached by the appointed lead plaintiff and the defendants. Importantly, class members do not need to file a separate claim immediately; rather, they become part of the class automatically if they meet the eligibility criteria and do not exclude themselves. However, if you are unsure whether you meet the class period dates or how many shares you held, it is advisable to consult with one of the law firms managing the action well before the May 26, 2026, deadline. Participation is free for class members, and recovery (if any) is distributed among all eligible claimants. Some investors mistakenly believe they cannot participate if they sold their shares at a loss; in fact, investors who purchased during the class period and later sold (or still hold) shares are eligible.
The Law Firms Pursuing the Class Actions and How Multiple Cases Affect Investors
Four prominent law firms have filed or are investigating claims on behalf of ImmunityBio investors: Rosen Law Firm (which filed the securities class action on March 26, 2026), Robbins Geller Rudman & Dowd LLP, Pomerantz LLP, and Portnoy Law Firm. While multiple lawsuits might initially seem confusing, they eventually consolidate or coordinate. Federal courts typically consolidate related securities class actions into a single proceeding to avoid inconsistent rulings and duplicate litigation expenses. Investors do not need to hire a private attorney; they can participate in the class action without paying upfront fees. The law firms’ compensation comes from a percentage of any recovery approved by the court. A key consideration is selecting which lawsuit or law firm to potentially designate as lead plaintiff counsel. While all four firms are reputable and experienced in securities litigation, they may have different track records, resources, and litigation strategies.
Some investors contact multiple firms to understand their approach before deciding whether to seek lead plaintiff status. The court will approve lead plaintiff counsel based on factors including the size of the investors’ holdings, their interest in the case, and the proposed counsel’s qualifications. However, if you do not seek lead plaintiff status, you remain part of the class regardless of which firm is appointed. One important warning: the existence of multiple class actions does not mean investors recover multiple times. Once consolidated or coordinated, investors participate in a single recovery pool. The recovery amount available for distribution depends on the strength of the case, the defendants’ ability to pay, and whether the defendants choose to settle or proceed to trial. Securities fraud cases can take several years to resolve, and recovery is never guaranteed.
The Broader Context: Cancer Drug Claims and Regulatory Scrutiny
Anktiva is an immunotherapy candidate in development for cancer treatment. Immunotherapies have shown genuine promise in treating certain cancer types by enlisting the body’s immune system to recognize and attack tumor cells. However, no single immunotherapy drug is effective against all cancers, and regulatory pathways require separate clinical evidence for each cancer indication. When promotional materials claim that a drug can “cure and prevent all cancer” types, they diverge sharply from how cancer medicines actually work and what the regulatory science demonstrates. The FDA has enforcement mechanisms specifically for drug misbranding.
When manufacturers make unsubstantiated health claims in advertising or promotional materials, the agency issues warning letters and can pursue additional regulatory action, including seizures of products or criminal referrals in egregious cases. The fact that the FDA targeted Anktiva’s promotional campaign signals that agency reviewers found the claims to be materially false or misleading. For investors, such regulatory action is a major red flag because it indicates that the company’s marketing strategy and the information being conveyed to the public do not align with what the FDA determines to be truthful and scientifically supported. This enforcement action also raises broader questions about what the company’s internal knowledge of Anktiva’s limitations might have been. If marketing teams were creating broad cure-and-prevention claims, did internal scientists and clinicians raise concerns? Were those concerns documented? Such internal materials often become crucial evidence in securities litigation, as they can show whether corporate leadership chose to ignore or suppress contrary information.
What Happens Next and Timeline for Potential Recovery
The lawsuits are in early stages. Once consolidated or coordinated, the case will move through discovery, during which both sides exchange documents, conduct depositions, and prepare for potential trial or settlement negotiations. Securities class actions typically take 2-5 years to resolve, depending on complexity, the strength of evidence, and whether defendants opt to settle early or contest the claims.
Some cases settle within months if the evidence is strong and the companies are motivated to resolve the matter; others proceed to trial and appeal. Investors who are appointed as lead plaintiff or participate in the litigation should expect periodic updates from their counsel about case developments, settlement negotiations, and any final approval hearing where the court evaluates whether a proposed settlement is fair and reasonable. Once a settlement or judgment is reached, class members are notified of the claims process and the deadline to submit a claim form if they wish to receive a payment. Settlements are rarely for the full amount of investor losses; they typically reflect a percentage of damages and are subject to attorney fees (usually 25-33% of the recovery) and court-approved costs.